SHH

OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE

Find entries where: SHH

is present as a standalone ligand in 17 entries

Find related ligands:

Chemical Component Summary
Name	OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Synonyms	SAHA
Identifiers	N-hydroxy-N'-phenyl-octanediamide
Formula	C₁₄ H₂₀ N₂ O₃
Molecular Weight	264.32
Type	NON-POLYMER
Isomeric SMILES	c1ccc(cc1)NC(=O)CCCCCCC(=O)NO
InChI	InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKey	WAEXFXRVDQXREF-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	39
Chiral Atom Count	0
Bond Count	39
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB02546 ?
Name	Vorinostat
Groups	approved investigational
Description	Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.
Synonyms	Octanedioic acid hydroxyamide phenylamide Vorinostat Suberoylanilide hydroxamic acid Suberanilohydroxamic acid SAHA Vorinostatum SHH
Brand Names	Zolinza
Indication	For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
Categories	Amides Amines Anilides Aniline Compounds Antineoplastic Agents Antineoplastic and Immunomodulating Agents Enzyme Inhibitors Histone deacetylase (HDAC) inhibitors Histone Deacetylase Inhibitors Hydroxamic Acids Hydroxy Acids Hydroxylamines Hyperglycemia-Associated Agents Immunosuppressive Agents Myelosuppressive Agents Narrow Therapeutic Index Drugs Potential QTc-Prolonging Agents QTc Prolonging Agents
ATC-Code	L01XH01
CAS number	149647-78-9

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Histone deacetylase 1	MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK...	unknown	inhibitor
Histone deacetylase 2	MAYSQGGGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYR...	unknown	inhibitor
Histone deacetylase 3	MAKTVAYFYDPDVGNFHYGAGHPMKPHRLALTHSLVLHYGLYKKMIVFKP...	unknown	inhibitor
Histone deacetylase 6	MTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGAVPRSIPNLAEV...	unknown	inhibitor
Histone deacetylase 8	MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYAL...	unknown
Acetoin utilization protein	MKKVKLIGTLDYGKYRYPKNHPLKIPRVSLLLRFLDAMNLIDEKELIKSR...	unknown
Histone deacetylase	MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682